XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Company Details
- Employees
- 113
- Founded
- 1999
- Phone
- 14086167210
- bd****@****ort.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- xenoport.com
- Keywords
- Representative jobs.
Xenoport, Inc. Questions
Xenoport, Inc.'s helpline number is 14086167210
Xenoport, Inc.'s website is xenoport.com
Xenoport, Inc.'s LinkedIn profile is https://www.linkedin.com/company/xenoport
Xenoport, Inc. has
113 employees.
View email and phone details for 113
employees at Xenoport, Inc..
Xenoport, Inc.'s industry is
Pharmaceutical Manufacturing
Xenoport, Inc.'s top competitors are
Amgen,
Bristol Myers Squibb,
Optivia Biotechnology,
Corcept Therapeutics,
Azurity Pharmaceuticals,
Inbios International,
Talphera, Inc.,
Nektar Therapeutics,
Ifm Therapeutics,
Dcvc.
Xenoport, Inc.'s support email address is bd@xenoport.com
Xenoport, Inc.'s categories are Pharmaceutical Manufacturing
Xenoport, Inc.'s founding year is 1999
